Cellular senescence — a state of irreversible cell cycle arrest characterized by a pro-inflammatory secretome — has emerged as a significant contributor to Alzheimer's disease (AD) pathogenesis. Often termed the "senescence-associated secretory phenotype" (SASP), this process drives chronic neuroinflammation and accelerates neurodegeneration.
| Trigger | Mechanism | Evidence |
|---|---|---|
| Aβ oligomers | DNA damage, oxidative stress | Postmortem AD brain studies |
| Tau pathology | Replication stress | Tau-transgenic mouse models |
| Oxidative stress | Telomere shortening | 8-OHdG accumulation |
| Mitochondrial dysfunction | mtDNA damage | Complex I deficiency |
| Chronic inflammation | SASP perpetuation | IL-6, IL-8 elevation |
Pro-inflammatory cytokines:
Chemokines:
Growth factors:
Proteases:
| Drug | Target | Clinical Status |
|---|---|---|
| Dasatinib + Quercetin | BCL-2, p53 | Phase trials |
| Navitoclax | BCL-xL, BCL-W | Preclinical |
| Fisetin | mTOR, JAK | Phase II |
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |
Overall Confidence: 62%